Application of terrain glucoside, an inhibitor of angiogenin secretion as a new drug for oral cancer therapy

2016 Fiscal Year Final Research Report

• Project/Area Number: 26463041
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Okayama University
• Principal Investigator: Kishimoto Koji 岡山大学, 医歯薬学総合研究科, 助教 (40243480)
• Co-Investigator(Renkei-kenkyūsha): YOSHIOKA Norie 岡山大学, 大学院医歯薬学総合研究科, 助教 (50362984)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: terrein / angiogenin / 口腔癌 / 血管新生作用 / 腫瘍増殖抑制作用 / 新規口腔癌治療薬 / angiogenin分泌抑制作用 / VEGF分泌抑制作用

Outline of Final Research Achievements

This study assessed the effect of terrain, a bioactive fungal metabolite on oral cancer. Terrein inhibited angiogenin and VEGF secretions from oral cancer cells, both HSC-2 and SAS. Terrein also directly inhibited the proliferation both of the cancer cells. Furthermore, terrain inhibited a HSC-2 xenograft tumor growth in athymic mice through the inhibition of tumor cell proliferation and angiogenesis. These results suggest that terrein has a new lead compound for oral cancer therapy.

Free Research Field

口腔外科学